Myriad announces diabetes collaboration with Sanofi
24 June 2014 | By Myriad RBM
Myriad Genetics announced that Myriad RBM has entered into a research collaboration with Sanofi...
List view / Grid view
News
Abbott to acquire Veropharm
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
MSD begins tender offer to acquire Idenix
23 June 2014 | By Merck
MSD is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
Sanofi reports positive Phase 3 results for Toujeo®
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
Janssen announces license agreement with Vertex to develop novel treatment for influenza A
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787...
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
18 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
New phase 3 study shows efficacy and safety of Victoza® for the treatment of type 2 diabetes in adults with moderate renal impairment
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
Biogen Idec and AbbVie announce positive top-line results from Phase 3 study investigating daclizumab high-yield process in multiple sclerosis
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
Oxford Global’s inaugural Drug Discovery USA Congress – Hot topics announced
16 June 2014 | By Oxford Global
After the continued success of the European Drug Discovery Summit Series, Oxford Global are pleased to announce the first Drug Discovery USA Congress...
AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma
12 June 2014 | By AstraZeneca
AstraZeneca announced a global licence agreement with Synairgen Plc for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma...
ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1
12 June 2014 | By GlaxoSmithKline
ViiV Healthcare announced that they have entered into an agreement with Janssen R&D Ireland Ltd for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®1)...
Sanofi and Regeneron announce new, detailed data from positive sarilumab Phase 3 rheumatoid arthritis trial at EULAR
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...
AVERT trial demonstrates high rates of DAS-defined remission with Orencia® (abatacept) in combination with Methotrexate in adult patients with early rheumatoid arthritis
11 June 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...